Supplementary Figure 4 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis | Synapse
July 15, 2025
Supplementary Figure 4 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis
Key Points
XPO1 inhibitor eltanexor modulates the Wnt/beta-catenin signaling pathway in colorectal cancer.
Study shows eltanexor does not change beta-catenin protein expression levels in treated cells.
Figure S4 illustrates that eltanexor does not affect intracellular localization of beta-catenin.
Findings suggest potential therapeutic implications of eltanexor without altering key signaling components of tumorigenesis.
Abstract
Figure S4. Eltanexor does not changes β-catenin protein expression or intracellular localization.